Dr Mark Kris breaks down the lazertinib-amivantamab data, noting that the combo shows benefit but fails to address key ...
ArriVent BioPharma's furmonertinib demonstrates robust efficacy, CNS penetration, and tolerability in early trials. Read why ...
First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s ...
Chinese pharma Hansoh Pharma (HKEX: 3692) has secured approval from China’s National Medical Products Administration for an ...
With durable responses, encouraging survival outcomes, and evidence that some patients may become eligible for ...
Researchers have found in a new study that an eGFRcys value that is 30% or more lower than eGFRcr was associated with ...
Tovia Anyanwu, a kidney failure survivor, shares her shocking diagnosis after childbirth, her family's struggle, and how ...
In Brazil, the early detection of genetic alterations in lung cancer through liquid biopsies could be a valuable tool for ...
EpiBiologics launched in 2023 with a $50 million series A, having been founded to take forward the work of renowned antibody ...
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best affordable stocks with good earnings growth for 2026. Halozyme ...
New research from the University of Minnesota Medical School offers a new view of how the immune system responds to organ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback